TABLE 2

Soleus and EDL weights and Na+,K+-ATPase activity in control, diabetic (STZ), and PKF275–055-treated diabetic rats subjected to therapeutic or prolong prevention schedules at day 78 after STZ injection

Results are means ± S.E.M.

GroupMuscle WeightBody Weight/Muscle WeightNa+,K+-ATPase Activity
SOLEDLSOLEDL
mgg/mgμmolPi/h/mg protein
Control204 ± 5.7221 ± 7.02.48 ± 0.082.30 ± 0.080.58 ± 0.06
Control + PKF210 ± 4.2227 ± 4.32.43 ± 0.082.25 ± 0.070.60 ± 0.06
STZ untreated99 ± 9.8*73 ± 8.7**2.47 ± 0.073.24 ± 0.15*0.35 ± 0.03***
STZ + PKF therapeutic102 ± 3.7*95 ± 4.6**§2.63 ± 0.082.86 ± 0.08**0.60 ± 0.04§
STZ + PKF prolong prevention122 ± 6.6*108 ± 4.5**§2.43 ± 0.032.74 ± 0.07§0.54 ± 0.05
  • * P < 0.001 vs. CTRL and CTRL + PKF.

  • ** P < 0.005 vs. CTRL and CTRL + PKF.

  • *** P < 0.01 vs. CTRL and CTRL + PKF.

  • § p < 0.05 vs. STZ untreated.